Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Symbicort Intervention in Airway Predominant COPD
NCT01253473Phase 4Completed
- Sponsor
- National Jewish Health
- Start
- Apr 2012
- Primary completion
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of budesonide and formoterol in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by National Jewish Health. Primary endpoint: Forced Expiratory Volume in 1 Second (pre-bronchodilator) at 12 weeks. Started Apr 2012; status: completed.
02
Drugs
budesonideformoterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT01253473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01253473.